Evolus Inc（EOLS）股票分析EOLSEvolus Inc

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Evolus Inc is currently not a strong buy due to its recent FDA warning and insider selling, despite a positive long-term outlook. The current price is $7.01, with an RSI of 31.189 indicating oversold conditions. However, the stock has seen a 5-day change of -1.27% and a 20-day change of -12.05%, suggesting bearish momentum. The main risk is the FDA's misleading promotion allegations, which have already led to a 6.5% drop in stock price.

4 analysts cover EOLS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 19.25.